logo
Sign in

PIRAMAL PHARMA LIMITED (PPLPHARMA) financials

PIRAMAL PHARMA LIMITED (PPLPHARMA) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions[…

  • Market Cap: ₹26,325Cr.
  • Current Price: ₹198
  • Stock P/E: 34.0
  • ROE: 9.84%
  • ROCE: 11.8%
  • Book Value: ₹61.2
  • Dividend Yield: 0.00%
  • 52W High / Low: ₹232/132

In Jun 2026, PIRAMAL PHARMA LIMITED (PPLPHARMA) reported sales ₹1,125 Cr and net profit ₹113 Cr.

Annual TTM: sales ₹4,937 Cr, net profit ₹700 Cr.

Shareholding: Promoters 34.80% (Jun 2026), FIIs 12.51% (Jun 2026), DIIs 14.57% (Jun 2026), Public 37.62% (Jun 2026), Others 0.48% (Jun 2026).

PPLPHARMA quarterly results (₹ Cr.)
CategorySep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,2841,2481,6909701,1271,1961,4891,125
Expenses1,0321,0291,2739261,0001,0291,1861,008
Operating Profit25321941744127167303117
OPM %20%18%25%4.6%11%14%20%10%
Other Income106254018120269118115
Interest3029312320172016
Depreciation5455615961657066
Profit before tax276159364143247155332149
Tax %24%25%24%21%21%17%21%24%
Net Profit210119277113196129262113
EPS in Rs1.580.902.090.851.480.971.970.85
Raw PDF————————
PPLPHARMA profit and loss (₹ Cr.)
CategoryMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,9393,3403,4434,3905,2864,7824,937
Expenses2,3202,8643,3453,7724,2454,1404,222
Operating Profit619476986181,040642715
OPM %21%14%2.8%14%20%13%14%
Other Income216209334202207570504
Interest5571161071158073
Depreciation144165192205222256262
Profit before tax687462124508911877884
Tax %17%20%44%23%24%20%—
Net Profit57236870391691700700
EPS in Rs——0.532.965.225.275.27
Dividend Payout %0%18%0%4%3%0%—
PPLPHARMA balance sheet (₹ Cr.)
CategoryMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital9951,1861,1931,3231,3241,327
Reserves3,1063,9374,0685,3896,1286,814
Borrowings1741,1641,6491,1771,243786
Other Liabilities1,4821,0831,1311,6621,6962,826
Total Liabilities5,7577,3718,0429,55110,39211,753
Fixed Assets1,6272,4392,6022,6122,8943,036
CWIP121405417533327221
Investments1,5921,6301,7471,7083,1053,580
Other Assets2,4172,8973,2774,6974,0654,917
Total Assets5,7577,3718,0429,55110,39211,753
PPLPHARMA cash flows (₹ Cr.)
CategoryMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity35249723585491,328
Cash from Investing Activity-4,383-1,165-435-635-552-318
Cash from Financing Activity4,494896290451-62-615
Net Cash Flow146-19-73175-65395
Free Cash Flow-2018-171332671,040
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit21%74%135%71%75%225%
PPLPHARMA shareholding pattern (%)
CategorySep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters34.94%34.94%34.94%34.85%34.85%34.85%34.85%34.80%
FIIs31.73%31.68%31.49%30.86%30.27%29.66%30.17%12.51%
DIIs13.80%14.09%14.78%14.25%14.89%15.68%15.61%14.57%
Public19.06%18.85%18.42%19.46%19.46%19.35%19.01%37.62%
Others0.45%0.40%0.34%0.57%0.51%0.44%0.34%0.48%
No. of Shareholders3,59,7514,18,4424,32,8434,58,4304,62,5114,53,8304,50,6614,61,096
PPLPHARMA key ratios
CategoryMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days10410896111115107
Inventory Days125125169200196330
Days Payable174151157192193355
Cash Conversion Cycle568210811911883
Working Capital Days183825637374
ROCE %—10%4%8%12%12%
PPLPHARMAUpdated 19 Oct 2026, 1:09

Piramal Pharma Limited

Market Cap

₹26,325Cr.

Current Price

₹198

High / Low

₹232/132

Stock P/E

34.0

ROE9.84%
ROCE11.8%
Book Value₹61.2
Face Value₹10.0
Dividend Yield0.00%

About

Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions[1]and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion[2]and Diagnostic Services was sold to Super Religare Laboratories (SRL)[3]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Jun 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios
CategoryMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days10410896111115107
Inventory Days125125169200196330
Days Payable174151157192193355
Cash Conversion Cycle568210811911883
Working Capital Days183825637374
ROCE %—10%4%8%12%12%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of PIRAMAL PHARMA LIMITED (PPLPHARMA)?

The reported market capitalisation for PIRAMAL PHARMA LIMITED (PPLPHARMA) is ₹26,325Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of PPLPHARMA?

The current price shown for PIRAMAL PHARMA LIMITED (PPLPHARMA) on Fincrux is ₹198 with a 52-week high/low of ₹232/132.

What is the P/E ratio of PIRAMAL PHARMA LIMITED (PPLPHARMA)?

The stock P/E for PIRAMAL PHARMA LIMITED (PPLPHARMA) is 34.0 on Fincrux, with ROE at 9.84% and ROCE at 11.8%.

What were PPLPHARMA latest quarterly results?

For Jun 2026, PIRAMAL PHARMA LIMITED (PPLPHARMA) reported sales ₹1,125 Cr and net profit ₹113 Cr (figures in ₹ crore unless noted).

What are PPLPHARMA annual sales and net profit?

For TTM, PIRAMAL PHARMA LIMITED (PPLPHARMA) shows sales of ₹4,937 Cr and net profit of ₹700 Cr on the Fincrux profit & loss statement.

Who owns PIRAMAL PHARMA LIMITED (PPLPHARMA)?

Latest shareholding for PIRAMAL PHARMA LIMITED (PPLPHARMA) on Fincrux: Promoters 34.80% (Jun 2026), FIIs 12.51% (Jun 2026), DIIs 14.57% (Jun 2026), Public 37.62% (Jun 2026), Others 0.48% (Jun 2026).

Where can I find PIRAMAL PHARMA LIMITED (PPLPHARMA) financials?

PIRAMAL PHARMA LIMITED (PPLPHARMA) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show PPLPHARMA balance sheet and cash flow?

Yes. The PIRAMAL PHARMA LIMITED (PPLPHARMA) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 19 October 2026 at 1:09

Designed & Shipped by Harshit Bansal